Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral calcium gluconate for neonatal indirect hyperbilirubinemia during phototherapy
IRCT20260802070508N1Phase 3Not yet recruiting
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of calcium gluconate in indirect hyperbilirubinemia (IHB) (2 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoints: Serum indirect bilirubin level, Serum calcium level and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
calcium gluconate
03
Conditions
indirect hyperbilirubinemia (IHB)
Beyond the preview
Go deeper on IRCT20260802070508N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260802070508N1.